Pharmacy Daily | QBiotics is cashed up

Queensland-based life sciences company QBiotics Limited has more than $10 million to invest in its product pipeline of two oncology drugs and a wound treatment, after a successful capital raising over the last few months. $6.35m has been contributed by more than 270 private investors, with QBiotics ceo Victoria Gordon saying the money will support the firm “to reach some key milestones which could deliver significant value to our shareholders”. QBiotics is aiming to commence human trials for its lead oncology drug EBC-46 within six months, while the drug is also currently in mid clinical development as a veterinary pharmaceutical. “R&D work is already in full swing on our treatment for chronic wounds (WH-1) and our second oncology drug, EBC-23, will move into early preclinical in the near future,” Gordon said.

---

The above article was sent to subscribers in Pharmacy Daily's issue from 24 Sep 13
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Sep 13